<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: Fatty acid synthase (FAS) inhibitors could be a therapeutic target in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment </plain></SENT>
<SENT sid="1" pm="."><plain>However, only a few FAS inhibitors showing clinical potential have been reported </plain></SENT>
<SENT sid="2" pm="."><plain>Oridonin is a <z:chebi fb="0" ids="23849">diterpenoid</z:chebi> isolated from Rabdosia rubescens </plain></SENT>
<SENT sid="3" pm="."><plain>Although it has antiproliferative activity in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, little was known about its anticancer effect on <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>In this regard, we aimed to investigate if oridonin could be a novel FAS inhibitor and its anticancer mechanism in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="5" pm="."><plain>METHODS: Two human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cell lines SW480 and SW620 were used as models for this study </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: We demonstrated that oridonin <z:mp ids='MP_0010831'>reduced viability</z:mp> and induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="7" pm="."><plain>Knockdown of the expression of FAS in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells by siRNA induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>This led us to examine whether oridonin-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> was mediated by FAS suppression in these cells </plain></SENT>
<SENT sid="9" pm="."><plain>We found that oridonin effectively inhibited FAS and SREBP1 <z:chebi fb="2" ids="33699">mRNA</z:chebi> and protein expression in human <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> cells </plain></SENT>
<SENT sid="10" pm="."><plain>In a transient reporter assay, oridonin also reduced transcriptional activity of the FAS promoter region containing the SREBP1 binding site </plain></SENT>
<SENT sid="11" pm="."><plain>The FAS inhibition was paralleled by reduction in cellular <z:chebi fb="2" ids="29889">palmitate</z:chebi> and <z:chebi fb="0" ids="28842">stearic acid</z:chebi> </plain></SENT>
<SENT sid="12" pm="."><plain>Upregulation of SREBP1 and FAS expression by insulin rescued these cells from oridonin-induced <z:mpath ids='MPATH_3'>apoptosis</z:mpath> </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: These results not only provide a novel molecular mechanism for the anticancer effect of oridonin in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e>, but also suggest oridonin could be a novel FAS inhibitor in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> treatment </plain></SENT>
<SENT sid="14" pm="."><plain>These results strengthen the scientific basis for the therapeutic use of oridonin in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> </plain></SENT>
</text></document>